Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Molecular "Key" To Successful Blood Stem Cell Transplants Discovered By UBC

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology;  Stem Cell Research;  Transplants / Organ Donations
Article Date: 23 Apr 2009 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:3 and a half stars

3.25 (4 votes)

Health Professional:2 and a half stars

2.33 (3 votes)

Article Opinions: 0 posts

University of British Columbia researchers have discovered a "molecular key" that could help increase the success of blood stem cell transplants, a procedure currently used to treat diseases such as leukemia, Hodgkin's lymphoma and aplastic anemia.

During a blood stem cell transplant, donor blood stem cells - which can produce red and white blood cells and platelets - are injected into the recipient to produce new blood. The stem cells then need to travel to the thymus - an organ near the heart - and produce T-cells, a type of white blood cell that orchestrates the body's immune system.

A common problem with blood stem cell transplants is the failure of stem cells to repopulate the thymus and generate T-cells. Without T-cells the patient is unable to fight infection and post-transplant prognosis is poor.

Now Prof. Hermann Ziltener and his research team at UBC's Biomedical Research Centre have identified a molecule called S1P that can tell the thymus to "open the gates" and accept more stem cells.

"This discovery gives us a handle on determining whether the thymus will be receptive to migrating stem cells," says Ziltener, a professor in the Dept. of Pathology and Laboratory Medicine. "By treating patients with drugs that control S1P, scientists can now manipulate the thymic gates to either open or close."

The same team had previously identified a number of molecules that function as the thymic gates for migrating stem cells. The new study, published in the April issue of The Journal of Experimental Medicine, is the first to hone in on the "key" molecule that can open the thymic gate.

Next steps in the research include finding the mechanism T-cells in blood use to control S1P formation. Researchers estimate that it would be at least five years before the discovery can be translated into a clinical test.

Source:
Brian Lin
University of British Columbia


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Haiti Appeal

Haiti Appeal Image
The severe earthquake that struck Haiti has inflicted damage and devastation on a massive scale. Please donate to the Doctors Without Borders Haiti Appeal.

PLEASE DONATE HERE


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Multiple Myeloma? What Causes Multiple Myeloma?
25 Aug 2009
Multiple myeloma, also known as myeloma or plasma cell myeloma, is cancer of the plasma cells - a kind of white blood cell which is present in the bone marrow. Plasma cells make antibodies called immunoglobulin which help fight off infections...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...